$CW

Bamford Lynn M sold $1.9M of CW

Bamford Lynn M (Chair and CEO) sold 2,500 shares of CURTISS WRIGHT CORP (CW) at $758.20 ($1.90M total) on 2026-06-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bamford Lynn M
Published Jun 15, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CW
Neutral
medium confidence
Mentioned
$CW
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CWNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount, share count, and the confirmation that it was executed under a pre-arranged Rule 10b5-1 plan.

02

Market read

Traders may note the insider sale for sentiment, but there is no accompanying fundamental update in the text.

03

What to watch

The filing does not indicate any change in business outlook, guidance, or operational performance; without additional disclosures, the signal is weak.

Relevance 5/10Novelty 3/10Timing: Filed 2026-06-15, transaction dated 2026-06-12.

Background

The article is a SEC Form 4 insider transaction disclosure for Curtiss-Wright (CW).

Company-level read

Ticker impact

$CWNeutralMedium confidence
Context

Curtiss-Wright CEO Bamford Lynn M sold 2,500 shares at $758.20 each under a pre-arranged 10b5-1 plan, totaling $1.90M.

Expected impact

Likely limited near-term impact; any effect would be short-lived unless paired with other disclosures.

Evidence & confidence

Form 4 insider sales are common and the filing explicitly states a pre-arranged 10b5-1 plan, reducing the likelihood of immediate information content.

Market effects

No clear sector read-through from a single executive 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Insider sales can still reflect personal liquidity needs rather than bearish expectations, especially when the plan is pre-arranged.

Key entities

  • CURTISS WRIGHT CORP

    Subject of the Form 4 insider transaction disclosure.

  • Bamford Lynn M

    Chair and CEO who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CWMed

Curtiss-Wright Slides As Investors Question CEO Handoff

Curtiss-Wright (CW) shares fell as investors reacted to a planned leadership transition, with the current COO set to become CEO in 2027. Concerns about strategic continuity and execution risk were raised, despite the company's strong financial position and growth prospects. Quarterly results may be volatile due to cash conversion and supply chain pressures.

$CWMedAI 8/10

Why is Curtiss-Wright stock sliding today?

Curtiss-Wright stock fell 4.0% after announcing CEO Lynn M. Bamford will transition to Executive Chair, with COO Kevin M. Rayment succeeding in 2027. The change introduced strategic uncertainty, and the stock is near a 52-week low of $544.64, below its high of $808.16. The ex-dividend date is also approaching, adding to the pressure.

$CWMed

CW Initiated Coverage by Guggenheim -- Rating Upgraded to Buy

Guggenheim initiated coverage on Curtiss-Wright (CW) with a 'Buy' rating and a $786.00 price target. The stock is currently trading at $551.21, which is 24.3% above its GF Value™ of $443.58, indicating overvaluation. CW has a GF Score™ of 94/100, reflecting strong performance in growth and profitability, but a valuation rank of 5/10. Insider activity shows net selling of $705,928 over the last three months.

$CWMed

Curtiss Wright (CW) Wins New Defense Work, Is The Stock Cheap After The Selloff?

Curtiss-Wright (CW) secured $40M in contracts for the U.S. Army's air defense system. Its stock is down 24.3% over 30 days, but up 17.8% over 1 year. Analysts debate its valuation, with some seeing it as undervalued at $566.75, citing strong backlog growth and growth projections. The company trades at a P/E of 38.7x, lower than peers but higher than its own fair ratio of 24.8x.

$CWMed

Piper Sandler initiates Curtiss-Wright stock at neutral on valuation

Piper Sandler initiated coverage on Curtiss-Wright (NYSE:CW) with a Neutral rating and $665 price target, citing valuation concerns. The company reported Q2 earnings beating EPS estimates but missing on revenue. Curtiss-Wright's order book is up 12% YTD, and it raised its full-year outlook. Piper Sandler notes the stock's multiple expansion and potential overvaluation.

$CWHighAI 8/10

Curtiss-Wright reports strong Q2 2026 results and raises full-year guidance across defense, nuclear and industrial markets

Curtiss-Wright reported Q2 2026 sales of $924M, adjusted EPS of $3.72, and adjusted operating margin of 19.4%, all above expectations. The company raised full-year guidance to 8-9% sales growth and 14-16% EPS growth, with free cash flow outlook at $585M-$605M. New orders increased 8% YoY to $1.1B, and backlog reached $4.5B, up 10% from year-end 2025.